Form 4 for NUVB Nuvation Bio Inc.
Accepted 2025-11-26 00:00:00 ET · period of report 2025-11-25 · accession 0001937915-25-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-26 | 2025-11-25+ | NUVB | Liu Dongfang | Chief MEDICAL Off | S - Sale+OE | $7.75 | -20.0K | 18.0K | -53% | -$155.0K |
| DM | 2025-11-26 | 2025-11-25+ | NUVB | Liu Dongfang | Chief MEDICAL Off | M - OptEx | $3.61 | +20.0K | 28.0K | +250% | +$72.2K |
| DM | 2025-11-26 | 2025-11-25+ | NUVB | Liu Dongfang | Chief MEDICAL Off | M - OptEx | $0.00 | -20.0K | 470.0K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-11-25 | S | D | 10,000 | $7.50 | 18,000 | D | — | — | |
| 2 | Common | Class A Common Stock | 2025-11-26 | S | D | 10,000 | $8.00 | 18,000 | D | — | — | |
| 3 | Common | Class A Common Stock | 2025-11-25 | M | A | 10,000 | $3.61 | 28,000 | D | — | — | |
| 4 | Common | Class A Common Stock | 2025-11-26 | M | A | 10,000 | $3.61 | 28,000 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2025-11-25 | M | D | 10,000 | $0.00 | 480,000 | D | $3.61 · — to 2032-07-14 | 10,000 Class A Common Stock | (F1) Option vested as to 25% on the one year anniversary of 7/15/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2025-11-26 | M | D | 10,000 | $0.00 | 470,000 | D | $3.61 · — to 2032-07-14 | 10,000 Class A Common Stock | (F1) Option vested as to 25% on the one year anniversary of 7/15/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |